BR9909087A - Formulações para proteção de conjugados peg-alfa interferon - Google Patents

Formulações para proteção de conjugados peg-alfa interferon

Info

Publication number
BR9909087A
BR9909087A BR9909087-2A BR9909087A BR9909087A BR 9909087 A BR9909087 A BR 9909087A BR 9909087 A BR9909087 A BR 9909087A BR 9909087 A BR9909087 A BR 9909087A
Authority
BR
Brazil
Prior art keywords
peg
formulations
alpha interferon
present
conjugates
Prior art date
Application number
BR9909087-2A
Other languages
English (en)
Inventor
Douglas F Kline
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21957085&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9909087(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of BR9909087A publication Critical patent/BR9909087A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)

Abstract

Patente de Invenção: <B>''FORMULAçõES PARA PROTEçãO DE CONJUGADOS PEG-ALFA INTERFERON''<D>. A presente invenção fornece formulações para evitar a perda e deterioração de conjugados de PEG-alfa interferon, durante e após a liofilização. As formulações da presente invenção protegem os conjugados de PEG-alfa interferon da perda e degradação durante o processo de liofilização, assim como da degradação durante o armazenamento subseq³ente. As formulações da presente invenção são adequadas para proteção de conjugados de PEG-alfa interferon de diversos tipos de degradação, incluindo, mas não se limitando a isso, a perda da atividade biológica e mudanças no grau e/ou natureza da conjugação. Um conjugado de PEG-alfa interferon preferido que é protegido nas formulações da presente invenção é um conjugado de polietilenoglicol(PEG)(12000)-alfa-2b interferon.
BR9909087-2A 1998-03-26 1999-03-24 Formulações para proteção de conjugados peg-alfa interferon BR9909087A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4890798A 1998-03-26 1998-03-26
PCT/US1999/004268 WO1999048535A1 (en) 1998-03-26 1999-03-24 Formulations for protection of peg-interferon alpha conjugates

Publications (1)

Publication Number Publication Date
BR9909087A true BR9909087A (pt) 2000-12-05

Family

ID=21957085

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9909087-2A BR9909087A (pt) 1998-03-26 1999-03-24 Formulações para proteção de conjugados peg-alfa interferon

Country Status (25)

Country Link
EP (1) EP1066059B1 (pt)
JP (3) JP3643034B2 (pt)
KR (1) KR100420642B1 (pt)
CN (1) CN1191863C (pt)
AR (1) AR014772A1 (pt)
AT (1) ATE297761T1 (pt)
AU (1) AU754002B2 (pt)
BR (1) BR9909087A (pt)
CA (1) CA2324467C (pt)
CO (1) CO5080738A1 (pt)
CZ (1) CZ302005B6 (pt)
DE (1) DE69925820T2 (pt)
ES (1) ES2241272T3 (pt)
HU (1) HU228877B1 (pt)
ID (1) ID28470A (pt)
IL (2) IL138221A0 (pt)
MY (1) MY119227A (pt)
NO (1) NO329916B1 (pt)
NZ (1) NZ506631A (pt)
PE (1) PE20000338A1 (pt)
PL (1) PL193286B1 (pt)
PT (1) PT1066059E (pt)
SK (1) SK285284B6 (pt)
TW (2) TWI250024B (pt)
WO (1) WO1999048535A1 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999048535A1 (en) * 1998-03-26 1999-09-30 Schering Corporation Formulations for protection of peg-interferon alpha conjugates
US6605273B2 (en) 1999-04-08 2003-08-12 Schering Corporation Renal cell carcinoma treatment
CA2303752A1 (en) * 1999-04-08 2000-10-08 Schering Corporation Renal cell carcinoma treatment
US6923966B2 (en) 1999-04-08 2005-08-02 Schering Corporation Melanoma therapy
US6362162B1 (en) 1999-04-08 2002-03-26 Schering Corporation CML Therapy
EP1251866A1 (en) * 2000-01-24 2002-10-30 Schering Corporation Combination of temozolomide and pegylated interferon-alpha for treating cancer
EP1908477A3 (en) * 2000-01-24 2008-06-11 Schering Corporation Combination of temozolomide and pegylated interferon-alpha for treating cancer
KR100353392B1 (ko) * 2000-03-13 2002-09-18 선바이오(주) 높은 생체 활성도를 갖는 생체 활성 단백질과 ｐｅｇ의결합체 제조방법
EP1279406A4 (en) 2000-04-03 2007-10-24 Santen Pharmaceutical Co Ltd TRANSPORTERS AND DRUG DISPENSING SYSTEMS USING THESE
CA2662899A1 (en) 2002-02-22 2003-09-04 Schering Corporation Pharmaceutical formulations of antineoplastic agents, in particular temozolomide, processes of making and using the same
AU2008201682B2 (en) * 2004-02-02 2011-02-24 Ambrx, Inc. Modified human interferon polypeptides and their uses
DE602005022895D1 (de) * 2004-08-12 2010-09-23 Schering Corp Stabile pegylierte interferon-formulierung
BRPI0821029A2 (pt) 2007-12-20 2015-06-16 Merck Serono Sa Fomulações de peg-interferon-beta
KR101303388B1 (ko) * 2010-10-26 2013-09-03 한미사이언스 주식회사 지속형 인터페론 알파 결합체의 액상 제제
KR20150074167A (ko) * 2012-10-26 2015-07-01 루핀 리미티드 Ｐｅｇ 인터페론 알파-2ｂ의 안정한 약학 조성물
KR101736870B1 (ko) 2014-08-20 2017-05-18 한국코러스 주식회사 인터페론 접합체를 포함하는 복합체 및 이의 제조방법
KR102783452B1 (ko) 2016-06-01 2025-03-19 세르비에 아이피 유케이 리미티드 폴리알킬렌 옥시드-아스파라기나제의 제형, 및 그의 제조 및 사용 방법
CN112358541B (zh) * 2020-11-25 2022-04-01 广州迪澳医疗科技有限公司 一种重组人γ-干扰素的冻干保护剂

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2024046A1 (en) * 1989-09-28 1991-03-29 Alberto Ferro Stabilized leukocyte-interferons
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
KR960705579A (ko) * 1993-11-10 1996-11-08 에릭에스. 딕커 개선된 인터페론 중합체 결합체(Improved interferon polymer conjugates)
US5766582A (en) * 1994-10-11 1998-06-16 Schering Corporation Stable, aqueous alfa interferon solution formulations
US5738846A (en) * 1994-11-10 1998-04-14 Enzon, Inc. Interferon polymer conjugates and process for preparing the same
JP2000510813A (ja) * 1995-02-06 2000-08-22 ジェネテイックス・インスティテュート・インコーポレイテッド Ｉｌ−１２用処方
TW426523B (en) * 1995-04-06 2001-03-21 Hoffmann La Roche Interferon solution
CA2226575C (en) * 1995-07-27 2011-10-18 Genentech, Inc. Stabile isotonic lyophilized protein formulation
PT858343E (pt) * 1995-11-02 2004-07-30 Schering Corp Terapia por infusao continua de uma dose baixa de citoquina
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
TW517067B (en) * 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
WO1999048535A1 (en) * 1998-03-26 1999-09-30 Schering Corporation Formulations for protection of peg-interferon alpha conjugates

Also Published As

Publication number Publication date
DE69925820D1 (de) 2005-07-21
ATE297761T1 (de) 2005-07-15
JP3643034B2 (ja) 2005-04-27
CA2324467C (en) 2002-11-05
PL345568A1 (en) 2001-12-17
JP4580744B2 (ja) 2010-11-17
PE20000338A1 (es) 2000-05-16
TW200536557A (en) 2005-11-16
CO5080738A1 (es) 2001-09-25
HUP0101749A2 (hu) 2001-11-28
DE69925820T2 (de) 2006-05-18
NZ506631A (en) 2003-03-28
CZ20003315A3 (cs) 2001-04-11
HK1029754A1 (en) 2001-04-12
AR014772A1 (es) 2001-03-28
KR100420642B1 (ko) 2004-03-02
SK14262000A3 (sk) 2001-04-09
PL193286B1 (pl) 2007-01-31
AU754002B2 (en) 2002-10-31
JP2002507583A (ja) 2002-03-12
MY119227A (en) 2005-04-30
ID28470A (id) 2001-05-24
NO20004785D0 (no) 2000-09-25
HUP0101749A3 (en) 2001-12-28
WO1999048535A1 (en) 1999-09-30
TWI250024B (en) 2006-03-01
HU228877B1 (en) 2013-06-28
CN1191863C (zh) 2005-03-09
JP2003221345A (ja) 2003-08-05
EP1066059B1 (en) 2005-06-15
NO20004785L (no) 2000-09-25
IL138221A0 (en) 2001-10-31
EP1066059A1 (en) 2001-01-10
CZ302005B6 (cs) 2010-09-01
TWI243057B (en) 2005-11-11
PT1066059E (pt) 2005-10-31
SK285284B6 (sk) 2006-10-05
NO329916B1 (no) 2011-01-24
CN1295484A (zh) 2001-05-16
ES2241272T3 (es) 2005-10-16
AU3181299A (en) 1999-10-18
CA2324467A1 (en) 1999-09-30
IL138221A (en) 2007-12-03
KR20010034654A (ko) 2001-04-25
JP2005104985A (ja) 2005-04-21

Similar Documents

Publication Publication Date Title
BR9909087A (pt) Formulações para proteção de conjugados peg-alfa interferon
TR200000481T2 (tr) N-Alkonoilfenilalenin türevleri.
CL2010000606A1 (es) Uso de derivados de eritropoyetina en la preparacion de un medicamento util para proteger, mantener, mejorar o recuperar la viabilidad de celulas que responden a eritropoyetina en condiciones anomalas que afectan las celulas, tejidos u organos asociados; derivados de eritropoyetinas y composicion que las comprende (divisional de la solicitud 3188-2001).
MX9305146A (es) Conjugado de interferon, procedimiento para su preracion y composicion farmaceutica que lo contienen.
TR199903053T2 (xx) Benzimidazol t�revleri.
MX9201298A (es) Nuevos conjugados de proteinas con poli etilen glicol, procedimiento para su preparacion y composicion farmaceutica que los contiene.
NO950291D0 (no) Farmasöytisk preparat inneholdende en tverrbundet kationisk polymer og en alkoksylert eter
NO20001567D0 (no) Bioadhesive sammensetninger og fremgangsmåter for topisk administrering av aktive midler
BR9811099A (pt) Inibidores de urocinase
WO2001051510A3 (en) G-csf conjugates
DE60031874D1 (de) Immunologisch relevante antigene aus herpes simplexvirus
BR9714164A (pt) Novos derivados de ácido fluoracrìlico, novas misturas de herbicidas e antìdotos e seu emprego
ATE330959T1 (de) Allosterische adenosin-rezeptor-modulatore
BR0012184A (pt) Derivados de indol
BR0012694A (pt) Conjugado de protease, composição de limpeza e composição de tratamento pessoal
MX9102101A (es) Composiciones que contienen psyllium. composiciones que contienen psyllium.
BR0014135A (pt) Composição farmacêutica fotoativável para destruição e/ou inaticação seletivas de células imunologicamente reativas, uso da mesma, e, métodos para prevenção de doença de enxerto-versus-hospedeiro associada com transplante alogênico de células tronco em um paciente, para tratamento de distúrbio imunológico em um paciente e para avaliar o mecanismo de transporte de células imunes e/ou malignas
BR0100954A (pt) Utilização de o-vanilina e combinações deo-vanilina/trolox(r)
BR9814188A (pt) &#34;agonistas de 5-ht1f&#34;
BR0208860A (pt) Uso de um derivado de dextrano catiÈnico, método para a proteção de um indivìduo contra o dano em órgãos com limitação de dose, e, método para a proteção de um indivìduo contra dano renal
TR200103151T2 (tr) Karboksipeptidaz U inhibitörü ile trombin inhibitörünü içeren farmasötik bir formülasyon.
SE9403905D0 (sv) New formulations
TR200000005T2 (tr) Sıtmaya karşı ß-alkoksiakrilatlar.
ES2126409T3 (es) Composicion gelificada estable que contiene agentes activos lipofilos sensibles al oxigeno y/o al agua.
FR2768145B1 (fr) Nouveaux composes derives d&#39;acide alkylene diamine di- ou tri-acetique, leur procede de preparation, leur utilisation dans des compositions cosmetiques et pharmaceutiques, et compositions les comprenant

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFERIDO O PEDIDO COM BASE NOS ARTIGOS 8O E 13O DA LPI.

B12B Appeal against refusal [chapter 12.2 patent gazette]
B25E Requested change of name of applicant rejected

Owner name: SCHERING CORPORATION (US)

B25H Request for change of headquarter rejected

Owner name: SCHERING CORPORATION (US)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08H Application fees: decision cancelled [chapter 8.8 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: A61K 9/19 (2006.01), A61K 38/21 (2006.0